银杏二萜内酯葡胺对急性缺血性卒中功能恢复的系统评价与Meta分析
该系统评价纳入8项RCT共4041例急性缺血性卒中患者,评价银杏二萜内酯葡胺(GDLM)联合常规治疗对功能恢复的影响。Meta分析显示,联合GDLM可显著提高90天优良功能结局(mRS 0-1)和良好功能结局(mRS 0-2)的比例,并降低mRS评分,证据确定性为中等。不良事件与反应发生率两组无显著差异。
要点
- GDLM联合常规治疗可提高AIS患者90天优良功能结局(mRS 0-1)比例,RR=1.16。
- GDLM联合常规治疗可提高良好功能结局(mRS 0-2)比例,RR=1.21。
- GDLM组90天mRS评分较对照组降低,MD=-0.66,证据确定性中等。
核心结论
- 中等确定性证据提示GDLM可能作为AIS患者改善功能结局的有益辅助治疗。
- GDLM联合常规治疗在功能恢复方面优于单纯常规治疗,且不良事件与反应发生率无显著差异。
- 仍需在未来实践中进一步验证GDLM在真实世界中的疗效与安全性。
研究设计与样本
- 系统评价与Meta分析,检索7个数据库自建库至2024年7月10日的随机对照试验(RCT)。
- 共纳入8项RCT,涉及4041例急性缺血性卒中患者。
- 进行了试验筛选、数据提取、偏倚评估、Meta分析及证据质量评价。
主要发现
- 与仅接受常规治疗(CTs)相比,GDLM联合CTs组达到优良功能结局(mRS 0-1)的比例显著更高(RR=1.16,95%CI 1.08-1.24,p<0.001)。
- GDLM联合CTs组达到良好功能结局(mRS 0-2)的比例显著更高(RR=1.21,95%CI 1.17-1.26,p<0.001)。
- GDLM联合CTs组90天mRS评分显著更低(MD=-0.66,95%CI -0.73至-0.59,p<0.001)。
- 两组不良事件和不良反应发生率无显著差异。
- 支持GDLM恢复功能独立作用的证据确定性评为中等。
关键数值与推荐
- 优良功能结局定义为mRS 0-1,良好功能结局定义为mRS 0-2。
- 功能结局评价时间点为90天。
- 证据确定性评级为中等(moderate)。
临床怎么用
- 对于急性缺血性卒中患者,可考虑在常规治疗基础上联合GDLM以改善90天功能结局。
- 临床决策时应结合中等确定性证据级别,并关注患者个体情况。
- 需在真实世界实践中进一步验证GDLM的疗效与安全性。
局限性
- 证据确定性仅为中等,需进一步验证。
- 原文未报告纳入RCT的具体偏倚风险细节。
- 原文未报告亚组分析或敏感性分析结果。
- 真实世界疗效与安全性尚待未来实践验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The clinical efficacy of ginkgo diterpene lactone meglumine (GDLM), a Chinese patent medicine, in acute ischemic stroke (AIS) has garnered attention. However, the impact of GDLM on functional recovery in AIS patients has not been systematically reviewed or meta-analyzed. AIM OF THE STUDY: To evaluate the functional outcomes of GDLM in AIS patients. MATERIALS AND METHODS: We conducted a search of seven databases from inception to July 10, 2024, for pertinent randomized controlled trials (RCTs). We performed trial selection, data extraction, and bias assessment. Meta-analysis was conducted to evaluate functional and safety outcomes. Quality of evidence was assessed. RESULTS: We included eight RCTs involving 4041 patients. Compared to those receiving only conventional treatments (CTs), patients treated with GDLM in combination with CTs exhibited a significantly higher proportion of patients achieving excellent (modified Rankin Scale [mRS] 0-1) or favorable functional outcomes (mRS 0-2) (risk ratio [RR] for excellent functional outcome = 1.16, 95% confidence interval [CI] 1.08 to 1.24, p < 0.001; RR for favorable functional outcome = 1.21, 95% CI 1.17 to 1.26, p < 0.001) and had lower mRS scores (mean difference [MD] = -0.66, 95% CI -0.73 to -0.59, p < 0.001) at 90 days. The evidence supporting GDLM's role in restoring functional independence was rated as moderate in certainty. Additionally, the incidences of adverse events and reactions did not differ significantly between the two groups. CONCLUSION: Moderate-certainty evidence suggests that GDLM may be a beneficial adjunct therapy for improving functional outcomes in AIS patients. Nonetheless, further validation of GDLM's efficacy and safety in real-world settings is warranted through future practice.
引用
- Wang L, Liang X, Chen Y, et al. Ginkgo diterpene lactone meglumine for functional recovery in patients with acute ischemic stroke: A systematic review and meta-analysis. J Ethnopharmacol. 2025. PMID: 39880062. doi:10.1016/j.jep.2025.119416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。